Compare MTSI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTSI | GH |
|---|---|---|
| Founded | 1950 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 14.8B |
| IPO Year | 2012 | 2018 |
| Metric | MTSI | GH |
|---|---|---|
| Price | $239.33 | $101.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $232.60 | $102.81 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,020,748,000.00 | $902,569,000.00 |
| Revenue This Year | $18.69 | $35.23 |
| Revenue Next Year | $13.24 | $27.38 |
| P/E Ratio | $109.32 | ★ N/A |
| Revenue Growth | 29.12 | ★ 30.38 |
| 52 Week Low | $84.00 | $34.88 |
| 52 Week High | $241.62 | $120.74 |
| Indicator | MTSI | GH |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 40.73 |
| Support Level | $225.98 | $100.26 |
| Resistance Level | $241.62 | $107.69 |
| Average True Range (ATR) | 13.23 | 6.19 |
| MACD | -0.10 | -1.38 |
| Stochastic Oscillator | 88.15 | 12.10 |
MACOM Technology Solutions Holdings Inc is a provider of analog, digital, and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.